These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 27618696)
1. Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-Series. Rishi P; Raka N; Rishi E PLoS One; 2016; 11(9):e0162533. PubMed ID: 27618696 [TBL] [Abstract][Full Text] [Related]
2. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion. Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576 [TBL] [Abstract][Full Text] [Related]
3. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions. Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion. Yang CS; Liu JH; Chung YC; Chou YB; Hung KH J Ocul Pharmacol Ther; 2015 Apr; 31(3):179-85. PubMed ID: 25715024 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH; Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042 [TBL] [Abstract][Full Text] [Related]
7. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142 [TBL] [Abstract][Full Text] [Related]
9. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
10. Extrafoveal changes following intravitreal bevacizumab injections for macular edema secondary to branch retinal vein occlusion: an mfERG and OCT study. Park S; Cho IH; Park TK; Nam WH; Ohn YH Doc Ophthalmol; 2013 Apr; 126(2):137-48. PubMed ID: 23255086 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Kim M; Jeong S; Sagong M Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671 [TBL] [Abstract][Full Text] [Related]
12. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Ehlers JP; Decroos FC; Fekrat S Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943 [TBL] [Abstract][Full Text] [Related]
14. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J; Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study. Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424 [TBL] [Abstract][Full Text] [Related]
17. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. Tsagkataki M; Papathomas T; Lythgoe D; Kamal A Semin Ophthalmol; 2015; 30(5-6):352-9. PubMed ID: 24875368 [TBL] [Abstract][Full Text] [Related]
18. Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels. Im JC; Shin JP; Kim IT; Park DH Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1267-74. PubMed ID: 26383643 [TBL] [Abstract][Full Text] [Related]
19. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Ahmadi AA; Chuo JY; Banashkevich A; Ma PE; Maberley DA Can J Ophthalmol; 2009 Apr; 44(2):154-9. PubMed ID: 19491948 [TBL] [Abstract][Full Text] [Related]
20. Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion. Yoo SJ; Kim JH; Lee TG; Kim JW; Cho SW; Han JI Korean J Ophthalmol; 2017 Apr; 31(2):95-101. PubMed ID: 28367036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]